MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Colofac MR 200mg capsules (Viatris UK Healthcare Ltd).

Stability Notes

Hygroscopic Protect from moisture. Airtight container. Maximum 7 days in MCA.

Provenance

Compatibility information derived from Avelox 400mg tablets (Bayer Plc) and Accord Healthcare Ltd product.

Stability Notes

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules.

Provenance

This compatibility recommendation is derived from Avodart 500microgram capsules (GlaxoSmithKline UK Ltd).

Stability Notes

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules.

Provenance

This compatibility recommendation is derived from Avodart 500microgram capsules (GlaxoSmithKline UK Ltd).

Stability Notes

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules.

Provenance

This compatibility recommendation is derived from Avodart 500microgram capsules (GlaxoSmithKline UK Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from all strengths of Lyrica capsules (Viatris UK Healthcare Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.